Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Abdollahi et al. Bioactive Carboxymethyl Starch-Based Hydrogels Decorated with CuO Nanoparticles: Antioxidant and Antimicrobial Properties and Accelerated Wound Healing In Vivo. <i>Int. J. Mol. Sci.</i> 2021, <i>22</i>, 2531.

International journal of molecular sciences·2026
Same author

Resensitizing drug-resistant cancers by co-targeting apoptosis and mitochondrial stress pathway.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same author

Key target genes of miR-625-5p in colorectal cancer: uncovering novel therapeutic targets within regulatory network.

Cancer treatment and research communications·2026
Same author

From lab to life: Advances in tissue engineering and 3D bioprinting for regenerative female reproductive health.

Tissue & cell·2026
Same author

Exosome-driven treatments for hair regrowth in androgenetic alopecia: a systematic review of preclinical studies, clinical experiments, safety, and future prospects.

Molecular biology reports·2026
Same author

Self-assembly for cuproptosis-based cancer therapy and imaging.

Chemical Society reviews·2026

Related Experiment Video

Updated: Jun 30, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Engineered extracellular vesicles for combinatorial cancer therapy and imaging.

Anita S La'ah1, Nashmin Fayazi Hosseini2, Choongmo Kang3

  • 1Taiwan International Graduate Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei 115, China.

Acta Pharmaceutica Sinica. B
|June 29, 2026
PubMed
Summary

Modified extracellular vesicles (EVs) offer a promising platform for cancer combination therapy, improving treatment efficacy and reducing side effects. This approach enhances cancer treatment strategies.

Keywords:
Cancer diagnosisCancer therapyCombination therapyDrug deliveryGene therapyImaging-guided therapyImmunotherapyModified extracellular vesicles

More Related Videos

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Related Experiment Videos

Last Updated: Jun 30, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Cancer treatment advances have improved survival, but challenges like drug resistance and toxicity persist.
  • Extracellular vesicles (EVs) are emerging as a key platform for drug delivery.
  • Current limitations necessitate innovative therapeutic strategies for improved cancer patient outcomes.

Purpose of the Study:

  • To review the use of engineered extracellular vesicles (EVs) for cancer combination therapy.
  • To highlight the potential of biocompatible EVs in inhibiting cancer progression with reduced side effects.
  • To explore EV biogenesis, sources, and their role in combination therapies and imaging-guided strategies.

Main Methods:

  • Literature review on engineered EVs for cancer therapy.
  • Analysis of EV biogenesis and sources.
  • Exploration of combination therapy and imaging-guided strategies using EVs.

Main Results:

  • Engineered EVs show potential for delivering combination therapies to inhibit cancer progression.
  • Biocompatible EVs can reduce off-target effects and systemic toxicity associated with cancer treatments.
  • EVs offer a versatile platform for integrating therapeutic and diagnostic modalities.

Conclusions:

  • Modified extracellular vesicles represent a promising and innovative platform for advanced cancer treatment.
  • The use of engineered EVs can overcome current therapeutic challenges, leading to improved patient outcomes.
  • Future research directions include optimizing EV engineering and exploring diverse EV sources for enhanced cancer therapy.